US 12,139,548 B2
Antibody that binds ErbB-2 and ErbB-3
Cecilia Anna Wilhelmina Geuijen, Utrecht (NL); Cornelis Adriaan De Kruif, Utrecht (NL); Mark Throsby, Utrecht (NL); Ton Logtenberg, Utrecht (NL); and Alexander Berthold Hendrik Bakker, Utrecht (NL)
Assigned to Merus N.V., Utrecht (NL)
Filed by Merus N.V., Utrecht (NL)
Filed on Oct. 19, 2022, as Appl. No. 18/047,933.
Application 17/675,431 is a division of application No. 15/121,623, granted, now 11,279,770, issued on Mar. 22, 2022, previously published as PCT/NL2015/050125, filed on Feb. 27, 2015.
Application 18/047,933 is a continuation of application No. 17/675,431, filed on Feb. 18, 2022.
Claims priority of application No. 14157360 (EP), filed on Feb. 28, 2014; and application No. 14167066 (EP), filed on May 5, 2014.
Prior Publication US 2023/0242669 A1, Aug. 3, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 31/185 (2006.01); A61K 31/337 (2006.01); A61K 31/436 (2006.01); A61K 31/4375 (2006.01); A61K 31/4439 (2006.01); A61K 31/519 (2006.01); A61K 39/395 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01)
CPC C07K 16/32 (2013.01) [A61K 31/185 (2013.01); A61K 31/337 (2013.01); A61K 31/436 (2013.01); A61K 31/4375 (2013.01); A61K 31/4439 (2013.01); A61K 31/519 (2013.01); A61K 39/39558 (2013.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 20 Claims
 
1. A method of treating a human subject having an ErbB-2, ErbB-3 or ErbB-2/ErbB-3 positive tumor comprising administering to the subject a bispecific antibody comprising:
a first binding arm that specifically binds to the extracellular domain of a human ErbB2 polypeptide and comprises a heavy chain variable region comprising the CDR1, CDR2, and CDR3 sequences of AYYIN (SEQ ID NO:49), RIYPGSGYTSYAQKFQG (SEQ ID NO:50), and PPVYYDSAWFAY (SEQ ID NO:51), respectively, and a light chain variable region comprising the CDR1, CDR2, and CDR3 sequences of a light chain comprising SEQ ID NO: 87; and
a second binding arm that specifically binds to the extracellular domain of a human ErbB3 polypeptide and comprises a heavy chain variable region comprising the CDR1, CDR2, and CDR3 sequences GYYMH (SEQ ID NO:64), WINPNSGGTNY AQKFQG (SEQ ID NO:65), and DHGSRHFWSYWGFDY (SEQ ID NO:66), respectively, and a light chain variable region comprising the CDR1, CDR2, and CDR3 sequences of a light chain comprising SEQ ID NO: 87.